The shift in myeloma cell dependence from BCL2 to MCL1 or BCLXL is the hallmark of acquired resistance to venetoclax in t(11;14) MM, as most responders eventually relapse (87, 88). The gene discussed is BCL2; the disease is plasma cell myeloma.